Northwestern Mutual Wealth Management Co. Has $11.65 Million Holdings in Gilead Sciences, Inc. $GILD

Northwestern Mutual Wealth Management Co. reduced its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 92,216 shares of the biopharmaceutical company’s stock after selling 6,273 shares during the quarter. Northwestern Mutual Wealth Management Co.’s holdings in Gilead Sciences were worth $11,651,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Paulson Wealth Management Inc. lifted its holdings in Gilead Sciences by 1.8% during the 4th quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock worth $477,000 after buying an additional 67 shares in the last quarter. Essex Financial Services Inc. boosted its stake in Gilead Sciences by 0.9% during the 4th quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock worth $948,000 after acquiring an additional 71 shares during the last quarter. Davidson Trust Co. boosted its position in shares of Gilead Sciences by 4.1% during the first quarter. Davidson Trust Co. now owns 1,879 shares of the biopharmaceutical company’s stock worth $262,000 after purchasing an additional 74 shares in the last quarter. Alpha Cubed Investments LLC grew its stake in Gilead Sciences by 1.1% in the fourth quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock valued at $812,000 after acquiring an additional 75 shares during the period. Finally, Financial Connections Group Inc. grew its position in shares of Gilead Sciences by 30.2% in the 1st quarter. Financial Connections Group Inc. now owns 328 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 76 shares during the period. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

Shares of NASDAQ:GILD opened at $149.61 on Thursday. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. The stock has a market capitalization of $185.51 billion, a price-to-earnings ratio of -56.03 and a beta of 0.33. Gilead Sciences, Inc. has a 1 year low of $108.46 and a 1 year high of $157.29. The company’s 50 day simple moving average is $135.66 and its 200 day simple moving average is $136.45.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, topping analysts’ consensus estimates of ($7.25) by $0.50. The firm had revenue of $7.80 billion during the quarter, compared to analysts’ expectations of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The business’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.01 earnings per share. As a group, research analysts predict that Gilead Sciences, Inc. will post -0.47 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be given a dividend of $0.82 per share. The ex-dividend date is Tuesday, September 15th. This represents a $3.28 annualized dividend and a yield of 2.2%. Gilead Sciences’s dividend payout ratio (DPR) is currently -122.85%.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 15,000 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $130.31, for a total transaction of $1,954,650.00. Following the completion of the sale, the chief executive officer owned 592,133 shares of the company’s stock, valued at approximately $77,160,851.23. This represents a 2.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $138.36, for a total transaction of $415,080.00. Following the sale, the chief financial officer owned 165,646 shares of the company’s stock, valued at approximately $22,918,780.56. This trade represents a 1.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 105,000 shares of company stock valued at $14,495,820 in the last quarter. Insiders own 0.30% of the company’s stock.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Zacks upgraded Gilead to “Strong Buy.” The upgrade reflects improving expectations for the company’s earnings outlook and could encourage additional buying interest. Gilead Upgraded to Strong Buy
• Positive Sentiment: Zacks raised its 2027 EPS forecasts across every quarter and for the full year. Estimates increased to $2.09 for Q1, $2.24 for Q2, $2.43 for Q3, $2.60 for Q4 and $9.36 for full-year 2027, signaling modestly stronger anticipated profitability. Zacks Gilead Upgrade and Forecasts
• Positive Sentiment: FDA approval of Bixlenvo expands Gilead’s HIV portfolio. The single-tablet treatment is aimed at underserved patients and could provide a new source of growth, though commercial adoption will determine its financial impact. Bixlenvo HIV Growth Opportunity
• Neutral Sentiment: CEO Daniel O’Day sold 15,000 shares worth approximately $2.23 million. The transaction reduced his holdings by 2.53%, but it was executed under a pre-arranged Rule 10b5-1 plan, making it a weaker bearish signal than an unexpected discretionary sale. SEC Insider Trading Filing

Analyst Ratings Changes

A number of equities analysts recently weighed in on GILD shares. Wall Street Zen raised shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, August 15th. Maxim Group raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 target price for the company in a research note on Wednesday, May 20th. Cantor Fitzgerald reiterated an “overweight” rating and set a $155.00 price target on shares of Gilead Sciences in a report on Wednesday, August 5th. Barclays decreased their price objective on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 29th. Finally, Truist Financial decreased their target price on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating on the stock in a research report on Tuesday, July 7th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $158.04.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.